Last reviewed · How we verify
NCT06651112: ATP
The ATP Project (Antipsychotic-TEP-Psychosis)
trial testing Antipsychotic drugs in First Episose Psychosis in 18 participants. Not yet recruiting.
1 November 2026
Quick facts
| Lead sponsor | Université de Sherbrooke |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 1 November 2024 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Antipsychotic drugs — full drug profile →
Conditions studied
- First Episose Psychosis — all drugs for First Episose Psychosis →
- Metabolic Disease — all drugs for Metabolic Disease →
- Psychosis; Episode — all drugs for Psychosis; Episode →
Sponsor
Université de Sherbrooke — full company profile →
Who can join
Adults 18 to 35, any sex, with First Episose Psychosis or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis. The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose). Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Brain glucose and ketone metabolism in first-episode psychosis: Neuroimaging and brain metabolism before and after antipsychotic treatment: The protocol for the CAST-ATP study.
Zemmour K, Samson GO, Fortier M, Parent E, et al · · 2025 · PMID 40587437 · DOI 10.1371/journal.pone.0325489
Verify or expand the search:
- PubMed search for NCT06651112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Antipsychotic drugs
Trials testing the same drug.
- NCT05039489 — A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia · NA · completed
- NCT04218981 — Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders · NA · completed
Other Université de Sherbrooke trials
Trials by the same sponsor.
- NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
- NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
- NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06651112 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06651112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing